D.E. Shaw & Co
LAB icon

D.E. Shaw & Co’s Standard BioTools LAB Stock Holding History

D.E. Shaw & Co’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,000
Closed -$588K – 4252
2014
Q2 		$588K Sell
20,000
-14,600
-42% -$468K ﹤0.01% 3396
2014
Q1 		$1.52M Buy
+34,600
New +$1.52M ﹤0.01% 2650

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

D.E. Shaw & Co's LAB Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Standard BioTools (LAB) in Q1 2026: 199,084 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #4220 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in LAB as recently as Q3 2023.

D.E. Shaw & Co first reported a position in LAB in Q2 2013 and has held it in 34 quarters since. The position peaked at $12.4M in Q1 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • D.E. Shaw & Co held 199,084 shares of Standard BioTools worth $183K as of Q1 2026.
  • Standard BioTools was a new D.E. Shaw & Co position in Q1 2026.
  • Standard BioTools made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4220 holding.
  • D.E. Shaw & Co first reported a position in Standard BioTools in Q2 2013 and has held it in 34 quarters since.
  • D.E. Shaw & Co's Standard BioTools position peaked at $12.4M in Q1 2019.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.